Syros to Participate in Upcoming Virtual Investor Conferences in March

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in two virtual investor conferences in March. She will present at the Cowen 42nd Annual Healthcare Conference on March 7 at 12:50 p.m. ET and at the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 3:20 p.m. ET. Management will also hold one-on-one meetings. Archived recordings will be available on Syros' website.

Syros focuses on developing gene expression medicines with a diverse clinical pipeline, including treatments for myelodysplastic syndrome, acute myeloid leukemia, and solid tumors.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:

Cowen 42nd Annual Healthcare Conference
Date: Monday, March 7
Panel Title: Novel Oncology Targets
Panel Time: 12:50 p.m. ET

Oppenheimer 32nd Annual Healthcare Conference
Date: Wednesday, March 16
Presentation Time: 3:20 p.m. ET

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005020/en/

Media Contact:

Courtney Solberg

Syros Pharmaceuticals

917-698-9253

csolberg@syros.com

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

What are the dates and times for Syros Pharmaceuticals' upcoming investor conferences?

Syros Pharmaceuticals will present at the Cowen 42nd Annual Healthcare Conference on March 7 at 12:50 p.m. ET and at the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 3:20 p.m. ET.

Who will represent Syros Pharmaceuticals at the investor conferences?

CEO Nancy Simonian will represent Syros Pharmaceuticals at the upcoming investor conferences.

Where can I access the webcasts of Syros Pharmaceuticals' presentations?

The webcasts can be accessed in the Investors & Media section of Syros Pharmaceuticals' website.

What is the focus of Syros Pharmaceuticals' clinical pipeline?

Syros Pharmaceuticals focuses on developing gene expression medicines for diseases like myelodysplastic syndrome, acute myeloid leukemia, and various solid tumors.